Acute liver failure differential diagnosis: Difference between revisions
Ahmed Younes (talk | contribs) No edit summary |
|||
(33 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | [[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Acute_liver_failure]] | ||
{{ | {{CMG}} {{AE}} {{HS}} | ||
==Overview== | ==Overview== | ||
Acute liver failure must be differentiated from other diseases that cause signs and symptoms of [[jaundice]], [[coagulopathy]], and [[encephalopathy]]. The differentials include [[acute hepatitis]], [[cholestatic jaundice]], and [[Hemolytic|hemolytic jaundice]]. The common causes of [[acute hepatitis]] causing acute liver failure include [[acetaminophen toxicity]], [[viral hepatitis]], [[alcoholic hepatitis]], [[autoimmune hepatitis]], [[acute fatty liver of pregnancy]], [[Wilson's disease]], [[ischemic hepatitis]] and hepatic congestion due to [[right heart failure]] and [[Budd-Chiari syndrome|Budd–chiari syndrome]]. | |||
==Differentiating Acute Liver Failure from other Diseases== | ==Differentiating Acute Liver Failure from other Diseases== | ||
Acute liver failure must be differentiated from other diseases that cause signs and symptoms of [[jaundice]], [[coagulopathy]], and [[encephalopathy]].<ref name="pmid17370334">{{cite journal| author=Escorsell A, Mas A, de la Mata M, Spanish Group for the Study of Acute Liver Failure| title=Acute liver failure in Spain: analysis of 267 cases. | journal=Liver Transpl | year= 2007 | volume= 13 | issue= 10 | pages= 1389-95 | pmid=17370334 | doi=10.1002/lt.21119 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17370334 }} </ref><ref name="pmid17608778">{{cite journal| author=Bower WA, Johns M, Margolis HS, Williams IT, Bell BP| title=Population-based surveillance for acute liver failure. | journal=Am J Gastroenterol | year= 2007 | volume= 102 | issue= 11 | pages= 2459-63 | pmid=17608778 | doi=10.1111/j.1572-0241.2007.01388.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17608778 }} </ref><ref name="pmid20196116">{{cite journal| author=Kumar R, Shalimar. Bhatia V, Khanal S, Sreenivas V, Gupta SD et al.| title=Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome. | journal=Hepatology | year= 2010 | volume= 51 | issue= 5 | pages= 1665-74 | pmid=20196116 | doi=10.1002/hep.23534 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20196116 }} </ref><ref name="pmid22213561">{{cite journal| author=Lee WM, Stravitz RT, Larson AM| title=Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. | journal=Hepatology | year= 2012 | volume= 55 | issue= 3 | pages= 965-7 | pmid=22213561 | doi=10.1002/hep.25551 | pmc=3378702 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22213561 }} </ref> | |||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" align="center" | |||
| valign="top" | | |||
|+ | |||
! style="background: #4479BA; width: 200px;" | Condition | |||
! style="background: #4479BA; width: 300px;" | Differentiating signs and symtoms | |||
! style="background: #4479BA; width: 300px;" | Differentiating Tests | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |Acute hepatits | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
* [[Jaundice]] and [[coagulopathy]] may be present. | |||
* Severe [[acute hepatitis]] is followed very closely as it has a potential to develop into acute or subacute hepatic failure. | |||
* Acute hepatitis would not be considered acute liver failure unless [[hepatic encephalopathy]] is present. | |||
* Common causes are [[viral hepatitis]], [[acetaminophen overdose]], [[alcoholic hepatitis]], [[autoimmune hepatitis]] and [[Metabolic disorder|metabolic disorders]] such as [[Wilson's disease]] and [[hemochromatosis]]. | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
* [[Hepatic encephalopathy]] is absent. | |||
* Grades of hepatic encephalopathy are: | |||
** Grade 1: Trivial lack of awareness; [[euphoria]] or [[anxiety]]; shortened attention span. | |||
** Grade 2: Lethargy or [[apathy]]; minimal [[disorientation]] for time or place; subtle personality change; inappropriate behavior; impaired performance of subtraction. | |||
** Grade 3: [[Somnolence]] to semi-stupor, but responsive to verbal stimuli; [[confusion]]; gross disorientation. | |||
** Grade 4: [[Coma]] (unresponsive to verbal or noxious stimuli). | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |Cholestasis | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
* [[Jaundice]] can be seen due to intra or extrahepatic [[biliary obstruction]], as well as intrahepatic [[cholestasis]] due to conditions like drug-induced liver injury. | |||
* The absence of [[hepatic encephalopathy]] and [[coagulopathy]] will differentiate it from acute liver failure. | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
* Absence of [[Hepatic encephalopathy|hepatic encephalopathy.]] | |||
* [[INR|Normal PT/INR.]] | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |Hemolysis | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
* May have [[jaundice]] with increased ([[Unconjugated bilirubin|unconjugated]]) indirect serum [[bilirubin]]. | |||
* Liver dysfunction may not be present. So, [[coagulopathy]] and [[hepatic encephalopathy]] would not be there. | |||
* Common examples are [[hemolytic anemias]]. | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
* Absence of [[Hepatic encephalopathy|hepatic encephalopathy.]] | |||
* Normal [[Prothrombin time|PT/INR]]. | |||
* Abnormal [[Peripheral blood smear|peripheral blood smear.]] | |||
|} | |||
<span style="font-size:85%">'''Abbreviations:''' | <span style="font-size:85%">'''Abbreviations:''' | ||
'''[[RUQ]]'''= Right upper quadrant of the abdomen, '''LFT'''= Liver function test, SIRS= [[Systemic inflammatory response syndrome]], '''[[ERCP]]'''= [[Endoscopic retrograde cholangiopancreatography]], '''N'''= Normal, '''AMA'''= Anti mitochondrial antibodies, '''[[LDH]]'''= [[Lactate dehydrogenase]], '''GI'''= Gastrointestinal, '''CT'''= [[Computed tomography]]</span><br> | '''[[RUQ]]'''= Right upper quadrant of the abdomen, '''LFT'''= Liver function test, SIRS= [[Systemic inflammatory response syndrome]], '''[[ERCP]]'''= [[Endoscopic retrograde cholangiopancreatography]], '''N'''= Normal, '''AMA'''= Anti mitochondrial antibodies, '''[[LDH]]'''= [[Lactate dehydrogenase]], '''GI'''= Gastrointestinal, '''CT'''= [[Computed tomography]]</span><br> | ||
Line 102: | Line 115: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑/N | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑/N | ||
Line 115: | Line 128: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑↑ | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑/N | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑/N | ||
Line 161: | Line 174: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Dilated ducts on sono | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Dilated ducts on sono | ||
Line 175: | Line 188: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |HAV- AB | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |HAV- AB | ||
Line 189: | Line 202: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Positive serology | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Positive serology | ||
Line 203: | Line 216: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N/↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |N/↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑? | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |AMA positive | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |AMA positive | ||
Line 217: | Line 230: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N/↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |N/↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑? | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Beading on MRCP | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Beading on MRCP |
Latest revision as of 21:40, 8 February 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2]
Overview
Acute liver failure must be differentiated from other diseases that cause signs and symptoms of jaundice, coagulopathy, and encephalopathy. The differentials include acute hepatitis, cholestatic jaundice, and hemolytic jaundice. The common causes of acute hepatitis causing acute liver failure include acetaminophen toxicity, viral hepatitis, alcoholic hepatitis, autoimmune hepatitis, acute fatty liver of pregnancy, Wilson's disease, ischemic hepatitis and hepatic congestion due to right heart failure and Budd–chiari syndrome.
Differentiating Acute Liver Failure from other Diseases
Acute liver failure must be differentiated from other diseases that cause signs and symptoms of jaundice, coagulopathy, and encephalopathy.[1][2][3][4]
Condition | Differentiating signs and symtoms | Differentiating Tests |
---|---|---|
Acute hepatits |
|
|
Cholestasis |
|
|
Hemolysis |
|
|
Abbreviations:
RUQ= Right upper quadrant of the abdomen, LFT= Liver function test, SIRS= Systemic inflammatory response syndrome, ERCP= Endoscopic retrograde cholangiopancreatography, N= Normal, AMA= Anti mitochondrial antibodies, LDH= Lactate dehydrogenase, GI= Gastrointestinal, CT= Computed tomography
|
References
- ↑ Escorsell A, Mas A, de la Mata M, Spanish Group for the Study of Acute Liver Failure (2007). "Acute liver failure in Spain: analysis of 267 cases". Liver Transpl. 13 (10): 1389–95. doi:10.1002/lt.21119. PMID 17370334.
- ↑ Bower WA, Johns M, Margolis HS, Williams IT, Bell BP (2007). "Population-based surveillance for acute liver failure". Am J Gastroenterol. 102 (11): 2459–63. doi:10.1111/j.1572-0241.2007.01388.x. PMID 17608778.
- ↑ Kumar R, Shalimar. Bhatia V, Khanal S, Sreenivas V, Gupta SD; et al. (2010). "Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome". Hepatology. 51 (5): 1665–74. doi:10.1002/hep.23534. PMID 20196116.
- ↑ Lee WM, Stravitz RT, Larson AM (2012). "Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011". Hepatology. 55 (3): 965–7. doi:10.1002/hep.25551. PMC 3378702. PMID 22213561.